发明名称 |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
摘要 |
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
|
申请公布号 |
US2008234264(A1) |
申请公布日期 |
2008.09.25 |
申请号 |
US20070894160 |
申请日期 |
2007.08.20 |
申请人 |
THE GENERAL HOSPITAL CORPORATION;DANA FARBER CANCER INSTITUTE, INC. |
发明人 |
BELL DAPHNE WINIFRED;HABER DANIEL A.;JANNE PASI ANTERO;JOHNSTON BRUCE E.;LYNCH THOMAS J.;MEYERSON MATTHEW;PAEZ JUAN GUILLERMO;SELLERS WILLIAM R.;SETTLEMAN JEFFREY E.;SORDELLA RAFFAELLA |
分类号 |
A61K31/5377;A61K31/517;A61P35/00;C07K14/47;C12N15/12;C12Q1/48;C12Q1/68;G01N33/574;G01N33/74 |
主分类号 |
A61K31/5377 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|